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Background:  Lanreotide  Autogel/Depot  effectively  controls  symptoms  in  patients  with  carcinoid  syn-
drome  associated  with  neuroendocrine  tumours.  Data  on  patient-reported  outcomes  are  sparse.
Aim:  To  evaluate  the effect  of  lanreotide  on  patient-reported  outcomes  (PROs)  with  carcinoid  syndrome.
Methods:  This  was  an  international,  open-label,  observational  study  of  adults  with  neuroendocrine
tumours  and  history  of diarrhoea,  receiving  lanreotide  for >3 months  for  relief  of carcinoid  syndrome
symptoms.  The  primary  PRO measure  was  satisfaction  with  diarrhoea  control.  Secondary  PRO  measures
included  severity,  change  in symptoms  and  impact  on  daily  life  of diarrhoea;  and patient  satisfaction
with  flushing  control.
Results: Of  273  patients  enrolled,  76% were ‘completely’  or  ‘rather’  satisfied  with  diarrhoea  control;  79%
reported  improvement  in diarrhoea  with  lanreotide.  The  proportion  of  patients  with  ‘mild’,  ‘minimal’,
or  ‘no  diarrhoea’  increased  from  33%  before  treatment  to  75% during  treatment;  75%  were  unconcerned
about  the  impact  of diarrhoea  on  daily  life.  Satisfaction  with  flushing  control  amongst  patients  with
significant  flushing  at treatment  initiation  was  73%.
Conclusions:  Lanreotide  treatment  was associated  with  improvements  in  symptoms  as  well  as  a
range  of  PROs  in  patients  with  neuroendocrine  tumours  and  carcinoid  syndrome  (ClinicalTrials.gov:
NCT01234168).
©  2016  The  Authors.  Published  by Elsevier  Ltd on behalf  of  Editrice  Gastroenterologica  Italiana  S.r.l.
This  is an open  access  article  under  the  CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-∗ Corresponding author at: Service de Gastroentérologie-Pancréatologie, Hôpital
eaujon (Assistance Publique Hopitaux de Paris), 100 boulevard du Général Leclerc,
-92118 Clichy, France. Tel.: +33 1 40 87 53 28; fax: +33 1 42 70 37 84.
E-mail address: philippe.ruszniewski@bjn.aphp.fr (P. Ruszniewski).
ttp://dx.doi.org/10.1016/j.dld.2015.12.013
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1. Introduction
Neuroendocrine tumours (NETs) represent a heterogeneous
group of neoplasms, arising from neuroendocrine cells of the
endocrine system [1]. They can develop in almost any organ, but
occur most frequently in the lung, pancreas and gastrointestinal
tract [2]. NETs can be silent (non-functioning) or clinically symp-
tomatic (functioning). The latter are characterized by the secretion
of peptides and neurotransmitters; this, in turn, leads to the
erologica Italiana S.r.l. This is an open access article under the CC BY-NC-ND license
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evelopment of typical clinical syndromes [3,4]. For example, some
ETs release peptides and amines (e.g. serotonin), which produce
 characteristic set of symptoms called carcinoid syndrome (CS)
3,4]. CS occurs in approximately 10% of patients with metastatic
ETs [4] and is most prevalent in those with NETs of the small
ntestine (∼20%) [3]. The predominant symptoms of CS are flush-
ng (90%), diarrhoea (70%), and abdominal pain (40%) [3]. These
an be very distressing for patients and have a negative impact on
ealth-related quality of life (QoL) [5].
Surgery remains the only curative treatment for NETs presenting
ith early disease or metastatic disease amenable to curative
esection [6]; if this is not possible, locoregional treatment of
epatic metastases for selected patients has been advocated [7].
urrently approved systemic treatments to control tumor growth
n patients with midgut NETs are limited to somatostatin analogues
SSAs) [6–8].
Depot formulations of SSAs are currently considered the ‘stan-
ard of care’ for symptom control in CS [9]; these include lanreotide
Somatuline®) Autogel (Depot in the US), which is administered by
eep subcutaneous injection, and octreotide (Sandostatin®) LAR®,
hich is administered intramuscularly. SSAs such as lanreotide are
vailable in Europe and several other countries for the treatment
f CS, supported by clinical experience and clinical studies [9–13].
ost recently, a large international Phase III study, ELECT, which
as conducted in Europe and the US, demonstrated statistically
ignificant symptom relief with lanreotide based on reduced use of
 short-acting SSA [14].
In addition, there is evidence for SSAs as antitumour treatment.
n particular, a large, international, Phase III study, CLARINET has
emonstrated anti-tumour effects with lanreotide for metastatic
1 and G2 NET including midgut tumours [15]. A phase III study,
ROMID, also showed anti-tumour effects with octreotide in a
maller population of metastatic G1 midgut NET patients [16].
eptide receptor radio-targeted therapy with radiolabelled SSAs,
hich is used more commonly in Europe, may  also have thera-
eutic potential in NETs. Recently, a phase III study, NETTER-1,
howed that 177-Lu-Dotatate combined with a standard dose of
SA versus a high dose SSA alone was associated with a signif-
cant improvement in progression-free survival in patients with
rogressive midgut NETs [17].
To date, only a small number of NET clinical studies have exam-
ned both patient-reported outcomes (PROs) and QoL measures
ith current NET treatments [18]. These have mainly been stud-
es of SSAs and peptide receptor radio-targeted therapies, which
ave shown treatment was associated with stable or improved
oL outcomes in patients [11,13–15,19]. Most recently, the phase
II TELESTAR study of telotristat etiporate, a serotonin synthe-
is inhibitor under development, showed significant reductions
n bowel movements in patients with CS inadequately controlled
ith SSA, which was associated with treatment satisfaction and
erceived symptom relief reported by a subset of patients inter-
iewed after treatment [20]. However, no large prospective clinical
tudies have focused specifically on the impact of NET treatment
n patient-reported satisfaction with symptom control in a large
S patient population.
Here, we present the results of SymNET, a large multinational
bservational study of the real-world patient experience of CS
ymptom management at a single routine clinic visit at a num-
er of specialist centres. The main focus of the study was to
valuate a number of PRO measures – including the primary end-
oint, patient satisfaction with diarrhoea control – in NET patients
ho had received lanreotide Autogel/Depot. The study also eval-
ated medical records of physician-recorded CS symptoms and
ther patient characteristics at lanreotide initiation and at the
linic visit in order to explore their relationship with patient
atisfaction.ver Disease 48 (2016) 552–558 553
2. Methods
2.1. Patients
Adult patients (≥18 years) diagnosed with an NET were eligible
if they had been receiving lanreotide Autogel/Depot for >3 months
for relief of symptoms associated with CS, as indicated in their
medical records. In particular, all patients were required to have
a history of diarrhoea related to CS. Investigators were required to
recruit all consecutive eligible and consenting patients in order to
avoid recruitment bias.
Patients had to provide written informed consent to allow their
medical data to be collected, analyzed, and shared with regulatory
authorities.
2.2. Trial design and interventions
SymNET was a multinational, observational, non-interventional
study conducted between October 2010 (first patient enrolled) and
December 2012 (last patient visit) at 45 secondary or tertiary care
centres in eight countries (Czech Republic, France, Hungary, Israel,
Italy, Poland, Spain, and UK) (ClinicalTrials.gov: NCT01234168).
Patient recruitment and PRO assessment were conducted prospec-
tively during a single study visit; in addition, patient data were
collected from medical records.
The study did not impact on usual clinical management.
Patients’ clinic attendance and the exact prescription of lanreotide
or any other concomitant medications was unrestricted and in
accordance with routine clinical practice. The decision to prescribe
lanreotide was  made prior to, and independently from, the decision
to enrol patients in the present study.
The conduct of the study was in accordance with Good Phar-
macoepidemiological Practice Guidelines from the International
Society for Pharmacoepidemiology, and local regulatory require-
ments for non-interventional studies. The study was approved by
independent ethics committees/institutional review boards.
2.3. Assessments and endpoints
2.3.1. Patient-reported outcomes
During a routine clinic visit (assessment visit), patients were
asked by the physician to complete questionnaires. The primary
endpoint was  (i) patient-reported satisfaction with diarrhoea con-
trol (PSD) on the day of the visit. Secondary endpoints also collected
on day of visit included; (ii) diarrhoea severity and associated
impact on daily activities (assessed using a scale derived from the
clinical global impression of severity [CGI-S] scale); (iii) overall
change in diarrhoea symptoms at the time of the visit compared
with before treatment initiation (assessed using the patient global
impression of change [PGIC] scale); (iv) patient-reported feelings
and consequences of diarrhoea on daily life; (v) patient-reported
satisfaction with flushing control (PSF); and (vi) QoL evaluated
using the European Organization for Research and Treatment of
Cancer (EORTC) QLQ-C30 and QLQ-G.I.NET 21 questionnaires. See
full details of questionnaires in Supplementary Table S1.
Patient satisfaction with control of CS symptoms other than
diarrhoea and flushing was not measured as the primary focus was
diarrhoea control, and only limited numbers of patients enrolled
with other lesser symptoms.
2.3.2. Medical record review
During the assessment visit, as part of the routine consulta-tion, physicians reviewed patients’ medical records for information
on demographics, disease characteristics, treatment characteris-
tics, and diarrhoea and other CS symptoms at lanreotide initiation.
Physicians also collected information on patients’ diarrhoea and
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Table  1
Patient and disease characteristics.
Patients (n = 273)
Age at assessment visit, n (%)
31–40 years 7 (3)
41–50 years 40 (15)
51–60 years 69 (25)
61–70 years 86 (32)
>70 years 71 (26)
Men, n (%) 152 (56)
BMI  at assessment visit, kg/m2
Mean (SD) 25.0 (±4.7)
Median (range) 24.6 (14.2–47.8)
Time from diagnosis to assessment visit, years
Mean (SD) 4.4 (±4.5)
Median (range) 2.7 (0.3–22.4)
Tumour primary location, n (%) (n = 267)
Small bowel 176 (66)
Appendix 4 (1)
Right colon 10 (4)
Lung 11 (4)
Unknown 66 (25)
Tumour classificationa, n (%) (n = 252)
Well differentiated 203 (81)
Moderately differentiated 18 (7)
Unknown 31 (13)
Site  of metastases, n (%) (n = 271)
Any 251 (92)
Liver 217 (80)
Lymph nodesb 113 (42)
Peritoneum 43 (16)
Bone 16 (6)
Lung 14 (5)
Ovaries, uterus and uterine tubes 8 (3)
Otherc 6 (2)
CS  symptoms at assessment visit (n = 261–269d)
Diarrhoea 133 (49)
Flushes 90 (34)
Wheezing 5 (2)
Carcinoid heart disease 21 (8)
Previous NET surgery, n (%) (n = 271), 179 (66)
Primary tumour 152 (85)
Liver metastases 37 (21)
Primary tumour and liver metastases 31 (17)
Other 21 (12)
Concomitant NET treatments in previous 3 months, n (%) (n = 269), 61 (23)
Intravenous chemotherapy 19 (31)
Embolization or chemoembolization 16 (26)
Peptide receptor radionuclide therapy 15 (25)
Targeted therapy 15 (25)
Interferon alpha 4 (7)
SSA, somatostatin analogue; CS, carcinoid syndrome; SD, standard deviation.
a Tumour classification according to WHO  2000 classification as WHO  2012 grad-
ing not available at time of study;
b Two patients had metastases in the lymph nodes and spleen;
c Other metastatic sites: thyroid gland, duodenum, colon, pancreas, orbital, and
goitre;
N
o
p
t
r
a
c
2
a
9
a
td Diarrhoea N = 269, flushes N = 269, wheezing N = 264, carcinoid heart disease
 = 261 (also see Supplementary Table 2).
ther CS symptoms at study visit (this was used to determine
hysician recorded changes in diarrhoea and other CS symp-
oms between lanreotide initiation and study visit). Adverse drug
eactions were required to be reported to the manufacturer in
ccordance with standard procedures for clinical practice. No safety
ases were reported as arising.
.4. Statistical analyses
Estimated sample size, based on an anticipated PSD of 60%
nd precision of 5.5%, was  305 patients, assuming a two-sided
5% confidence interval (CI). For PSD-associated factors, assuming
lpha = 5% and power = 80%, estimated sample size was 323 patients
o detect an odds ratio (OR) ≥2 and a probability of exposure tover Disease 48 (2016) 552–558
any given level of a prognostic factor of ≥0.5. In order to ensure
323 evaluable subjects, 340 were to be included in the study. How-
ever, because of slow recruitment, the protocol was amended to
reduce patient numbers and enrolment ended in December 2012,
at which point >80% of the target number (i.e., >250 patients)
had been enrolled (see Supplementary Information for protocol
amendments).
The primary analysis population was all patients who  were
enrolled, provided consent and had data available for the rele-
vant endpoints. The primary endpoint (PSD) was  also analyzed for
the per-protocol (PP) population (all those enrolled with no major
protocol deviations). Descriptive methods were used for all other
endpoints on PRO measures or physician-recorded changes in CS
symptoms. PSD-associated factors were explored first using uni-
variate and then multivariate logistic regression analyses. Post hoc
analyses were conducted to evaluate physician-recorded changes
in diarrhoea characteristics according to PSD, and patient-reported
QoL according to PSD. Missing data were not replaced, and all end-
points were calculated based on patients with available data.
3. Results
3.1. Patient disposition and characteristics
Overall, 273 patients receiving lanreotide Autogel/Depot
attended the study visit and were enrolled in this study (ITT pop-
ulation); of these, 92% (252) were included in the PP population
(which excluded 19 patients whose lanreotide treatment was not
>3 months as per inclusion criteria). More than half of patients were
male (56% [152/273]) and >60 years of age (58% [157/273]). The
majority of ITT patients had midgut NETs (70% [190/273]), metas-
tasis (92% [251/271]), or had undergone surgery (66% [179/271]). In
total, 23% (61/269) received recent concomitant treatment as well
as lanreotide (Table 1).
The time between first diagnosis and lanreotide initiation was
highly variable (median [range], 0.63 [0,21.9] years). At study
visit, the mean (SD) lanreotide treatment duration was  21.7 (28.6)
months (median [range] was 10.9 [3–215] months). Almost all
patients were receiving lanreotide at standard doses of 60–120 mg
(60 mg, 28% [75/270]; 90 mg  and 120 mg,  each 35% [93/270]) and
at 4-weekly dosing intervals (93% [250/269]). Most patients (64%
[170/267]) had the same dose at study visit and treatment start.
Based on medical records, most common CS symptoms at study
visit were diarrhoea (49% [133/270]) and flushing (33% [90/269])
(Table 1). Diarrhoea and flushing symptoms were also estimated to
have occurred in 91% (244/269) and 165/269 (61%), respectively, at
lanreotide initiation (Supplementary Table S2). Note that the whole
study population was  selected based on a history of diarrhoea at
some point prior to the study. Of those patients for whom a reason
for diarrhoea was provided (n = 262), 30% (79) had another poten-
tial cause of diarrhoea in addition to CS. The most common were
small bowel resection (44% [35/79]), pancreatic insufficiency (32%
[25/79]), and ileocecal valve/colonic resection (24% [19/79]).
3.2. Patient-reported outcomes for carcinoid syndrome symptom
control
According to the primary PRO measure PSD, 76% of patients
(203/268) were ‘completely’ or ‘rather satisfied’ with diarrhoea
control at study visit (Fig. 1). Similar results were obtained in the PP
population (76%). PSD was lower for the patients with (66% [51/77])
versus those without (80% [152/194]) other contributing factors to
diarrhoea.
The secondary PRO measures also showed favourable patient
experience. Overall, 79% of patients (213/269) reported improved
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Fig. 1. Patient satisfaction with diarrhoea control associated with lanreotide treatment (primary endpoint).
Fig. 2. Patient satisfaction with diarrhoea control associated with lanreotide treatment. (a) Patient global impression of change. (b) Clinical global impression of severity.
Fig. 3. Patient satisfaction with flushing control associated with lanreotide treatment.
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Table  2
Factors associated with better patient satisfaction with diarrhoea control.
Variablesa included in multivariate
logistic regression analysis
Odds ratio [95% CI]; p value
(n = 212)b
Stool leakage at treatment initiation
No versus yes 0.31 [0.11, 0.89]; p = 0.029
Localization of primary tumour in small bowel
No versus yes 2.02 [0.93, 4.36]; p = 0.074
Body mass index (kg/m2) p = 0.143
<18.5 versus ≥18.5–25 0.80 [0.27, 2.43]
≥25 versus ≥18.5–25 1.71 [0.79, 3.69]
≥30 versus ≥18.5–25 3.85 [0.95, 15.60]
Treatment with prior long-acting SSAsc
No versus yes 1.69 [0.80, 3.57]; p = 0.165
4-week dose of lanreotide at
treatment initiation in mg p = 0.173
[60,90] versus ≤60 0.59 [0.25, 1.44]
[90,120] versus ≤60 0.80 [0.34, 1.90]
>120 versus ≤60 0.06 [0.00, 0.87]
CI, confidence interval; PSD, patient satisfaction with diarrhoea control; SSA,
somatostatin analogue.
a Variables shown above are those that were associated with patients’ satisfaction
at  a 20% level in univariate analyses, unless two variables were correlated, in which
case those at a lower significance level were excluded from the multivariate analysis.
b Associations were tested using the Chi-square test or Fisher’s exact test (if
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with good patient adherence [28] and patient perception of lan-xpected counts < 5).
c Long acting SSA include lanreotide microparticles and octreotide LAR.
iarrhoea after treatment (PGIC scale) (Fig. 2a). Proportion of
atients reporting ‘mild’, ‘minimal’, or ‘no diarrhoea’ also increased
fter treatment, from 33% (90/273) to 75% (205/273) on CGI-S
Fig. 2b). Less than one-third of patients answered with concern
o various questions about their diarrhoea or its consequences on
aily life (Supplementary Table S3). For PSF, 73% [107/147] of those
atients who reported experiencing significant flushing episodes at
reatment initiation were ‘completely’ or ‘rather satisfied’ with the
ontrol of flushing at study visit (Fig. 3).
.3. Physician-recorded changes in carcinoid syndrome
ymptoms
According to their medical records, patients had significantly
ower daily stool frequency at study visit than at lanreotide ini-
iation (mean [SD] stools/day: 4.7 [3.0] versus 2.6 [2.5]; mean
95% CI] reduction: 2.1 [1.7, 2.5]). In addition, there were fewer
atients with stool urgency, leakage and pain at study visit than
efore (Supplementary Table S2). At the study visit, 29% of patients
75/263) were receiving other treatments for diarrhoea, compared
ith 35% (93/269) at the time of lanreotide initiation. There were
ewer patients experiencing flushing episodes at lanreotide initia-
ion than at study visit (Supplementary Table S2).
Improvements in diarrhoea frequency, stool leakage, stool
rgency, and associated pain were more common among patients
eporting satisfaction with diarrhoea control than in those repor-
ing dissatisfaction or neither satisfaction nor dissatisfaction.
n those who were rather/completely satisfied, for stool fre-
uency, 78% showed improvements versus 22% who showed
o change/worsening. Similarly, for stool leakage, 18% showed
mprovement, 75% showed no change (remaining absent), 5%
howed no change (remaining present) and 3% showed worsening.
Univariate analysis of the association of patient characteristics
ith PSD identified nine factors that were potentially associated
ith better PSD (at the alpha = 0.10 level). In the multivariate anal-
sis, statistical significance (at the alpha = 0.05 level) was only
videnced for the association of stool leakage with better PSD, while
rimary tumour outside of small bowel showed a trend towards an
ssociation with better PSD (Table 2).ver Disease 48 (2016) 552–558
3.4. Patient-reported quality of life
According to the EORTC QLQ-C30 questionnaire at study visit,
patients had high levels of functioning for all scales and good global
QoL. Based on median scores (higher scores, worse symptoms),
the most problematic symptoms were fatigue, insomnia, and diar-
rhoea (median [range] = 33.3 [0–100] for all three symptoms) and,
to a lesser extent, pain (16.7 [0–100]); in contrast, the majority of
patients had no problems with vomiting, dyspnoea, appetite loss,
constipation, and financial difficulties (i.e. the median score was 0).
A similar pattern among symptoms was  apparent based on mean
scores.
Based on the median scores for the EORTC G.I.NET 21 question-
naire at study visit, problematic symptoms were disease-related
worries (44.4 [0–100]), social function (33.3 [0–100]), muscle/bone
pain (33.3 [0–100]) and, to a lesser extent, gastrointestinal (20.0
[0–100]) and endocrine symptoms (11.1 [0–100]). The major-
ity of patients had no problems with other symptoms, including
treatment-related effects, although a high mean value for sexual
function (31.3 [SD 37.4]) and, to a lesser extent, body image (19.6
[31.3]) suggests some patients found these aspects particularly
problematic.
More patients who  were satisfied with diarrhoea control
also reported EORTC QLQ-C30 global QoL scores as good/very
good/excellent (70%, 140/200) compared with patients who were
dissatisfied (39%, 7/18) or neither satisfied nor dissatisfied with
diarrhoea control (48%, 22/46).
4. Discussion
Data from this large real-world study demonstrate that
lanreotide Autogel/Depot not only improved physician-rated
symptoms in patients with CS and diarrhoea, but also a variety
of subjective PROs including patient satisfaction with diarrhoea
and with flushing. Satisfaction rates for diarrhoea control were
slightly lower in those with versus without other contributing fac-
tors to diarrhoea. It was also shown that factors associated with
even better satisfaction were the presence of stool leakage and pri-
mary tumour outside the small bowel. These data were obtained in
patients mostly receiving standard doses at standard dosing inter-
vals.
PROs are an important component of monitoring drug efficacy
and patient management, particularly for symptomatic conditions
such as CS and functional gastrointestinal disorders [21]. The
patient’s point of view on their health status is highly important,
can play a role in disease management decisions and its assess-
ment has the potential to enhance patient-centred care. Indeed,
PRO assessment has been advocated by regulatory authorities
[22,23]. Recent oncology clinical trials, to support clinical bene-
fits of new treatment options, have utilized endpoints on patient
preference [24] and symptom relief [25]. Furthermore, it has been
established that there is a relationship between patient prefer-
ence, adherence and clinical outcomes in patients with cancer
[26].
Although some previous studies have evaluated QoL in a limited
way for patients with NETs treatment, including some with lan-
reotide showing QoL benefits [11,13–15,27,28] there is a paucity of
detailed studies focusing on PROs following treatment for CS. The
current study, therefore, provides new and useful data. The results
are consistent with, and may  explain, at least in part, observations
that have shown once-monthly dosing of lanreotide is associatedreotide injection [29]. The results also underscore the utility of PROs
and that future studies assessing the efficacy of treatment of CS
should endeavour to include appropriate PRO endpoints.
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In the current study, patients’ QoL using the validated EORTC
uestionnaires was evaluated only at the study visit. This allows
enchmarking of the QoL in the current study against previous
tudies, in order to support the other new PRO measures in this
tudy, but it does not allow the treatment effect of lanreotide on
oL to be evaluated directly. The QoL scores obtained at the study
isit, which were consistent with the primary endpoint PSD, were
imilar to those reported from previous cross-sectional QoL surveys
f the general NET population [30–32].
Within the constraints of differences in study design and mea-
urement of outcomes, the results obtained for physician-reported
ontrol of carcinoid symptoms are broadly consistent with the
ndings of other studies of SSAs showing that lanreotide achieves
avourable rates of symptom control [9,11,12,33]. The recent ELECT
tudy showed that lanreotide achieved significant symptom relief
ersus placebo based on a one-third reduction in use of rescue
herapy over its 16-week double-blind phase [9]. A retrospective
tudy of 9 years’ clinical experience with lanreotide at a special-
st centre reported that 94% of patients had initial symptomatic
ontrol of flushing and stool frequency, and sustained control
n 54% after median follow-up of 27 months (range 7–93) [27],
hich are similar to the results in the current study obtained
ver a median treatment duration of 10.9 months (range 3–215)
27].
There are some important limitations that should be consid-
red when interpreting the SYMNET study data. Firstly, the PRO
easures in this study were completed only at one visit. These data
ere intended to provide an accurate “snapshot” of current patient
xperience in routine practice. They do not provide longitudinal
nformation. Secondly, the study intended to capture experience in
 general NET population in the real world, which would have vari-
ble treatment duration, dose and dosing interval for lanreotide.
hese results do not reflect those that would likely be observed
n a more restricted and homogenous clinical study population.
inally, inter-patient and within-patient variability are inherent to
ubjective PROs; however, the main PRO data were corroborated
y the objective data from medical records on CS symptoms and
he validated QoL questionnaires. Nevertheless, the major overall
trength of this study is its conduct in a large patient cohort in a
eal-life clinical setting, as this increases the external validity of the
esults.
In conclusion, lanreotide Autogel/Depot is an effective and con-
enient treatment for patients with NETs and associated CS. This
s supported by the PRO measures of symptom control used in this
tudy, which were consistent with physician-rated measures dur-
ng the study. PRO measures were also consistent with previous
linical data.
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